OR WAIT null SECS
© 2023 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
Lonza is making additional investments in its global particle engineering network for expanded capacity and specialized capabilities.
Lonza has announced, in a July 1, 2020 press release, that it is making additional investments in its global particle engineering network for expanded capacity and specialized capabilities.
Significant expansions have been made at United States and European sites in jet milling and spray dry processing for development, so that the company can meet increased demand for these services. Further enhancements have been made in specialized processing capabilities.
At the Monteggio (Switzerland) micronization site, development capacity (non-GMP assets) has been doubled, including investment in a new glove-box for isolation, upgraded process controls, and expanded operator teams. Additionally, a new micronization development wing has been brought online at the Quakertown, PA (US) site, and a new pharmaceutical spray dryer dedicated to development projects has been added to the Bend, OR (US) site.
“Particle engineering is a key component of our integrated services across drug substance and drug product development and manufacturing,” said Christian Dowdeswell, vice president, Small Molecules Commercial Development, Lonza, in the press release. “We see an increasing requirement for phase-appropriate jet milling and spray drying to advance complex molecules and meet more specialized target product profiles across oral and inhaled applications.”